SUPPORT OPPORTUNITIES FOR



Community ONcology CEllulaR Therapy Network

Friday, February 23, 2024

WESTIN INDIANAPOLIS | 241 W. WASHINGTON STREET | INDIANAPOLIS, IN

www.IndyHematologyReview.com | Indyhr@conventionnmanagers.com | 317-841-7171

COMMUNITY ONCOLOGY CELLULAR THERAPY NETWORK: CONCERT NETWORK Friday, February 23, 2024

INTRODUCTION

This is the third meeting on this critical topic. The first meeting of CONCERT network was held on March 17th, 2023, and the second meeting was September 30, 2023, at the Westin, Indianapolis.

Immune Effector and T-cell directed therapy, such as CAR T-cell therapy and T-cell engager treatments such as Bi-Specific antibody treatments, has revolutionized the treatment of hematologic malignancies. CAR T-cell treatment has its own limitations, and it often requires cumbersome manufacturing processes and is associated with high costs and appropriate infrastructure. Off the shelf therapies such bi-specific antibodies have been approved for the treatment of acute lymphoblastic leukemia, multiple myeloma, follicular lymphoma, and diffuse large B-cell lymphoma in the United States (US). Additionally other bi-specific antibodies are being developed for hematologic malignancies and other diseases. However, despite FDA approval of these agents, most patients being treated in the community do not have access to these agents due to concerns about potential adverse reactions and the required infrastructure. Additionally, most of the study clinical sites for these therapies have included few community oncology centers thus disadvantaging them from the ability to set up pre-approval infrastructure and subsequent implementation of immune effector therapies at community oncology centers.

Most patients with hematologic malignancies in the US are treated at community oncology practices, yet currently available therapies are delivered at academic centers with resultant non-diverse patients currently been offered these therapies and further worsening existing disparities in cancer care, particularly for these lifesaving therapies and exacerbating the nonavailability of clinical trial or real-world data of immune effector therapies for diverse populations.

The desire to provide modern cellular therapies to patients in the community, where most cancer patients in the US are treated, is the reason we created a NETWORK of community providers who are interested in establishing the infrastructure for cellular therapies and delivering such services to their patients. Cellular therapies in this definition would include bispecific antibodies, CAR-T therapies and other immunotherapies directed towards T-cells or malignant cells defined as appropriate for inclusion by the organization.

We believe the immediate needs of community oncology are to establish cellular therapies and immunotherapies focusing on the most pressing initial need for protocols and SOP's for managing bi-specific antibody-based therapies and subsequently creating an organization to promote the establishment of the infrastructure for the safe and effective administration of immune effector therapies, and the participation of good quality clinical trials with a focus on participant diversity.

AIMS and OBJECTIVES:

- 1. Refine clinical protocols and standard operating procedures (SOP's) for the safe and effective administration of immune effector therapies in community oncology practices.
- 2. Create infrastructure for the generation and collection of data across NETWORK.
- 3. Provide education for members and member institutions.
- 4. Establish a scalable training program for institutional staff, including but not limited to nursing, pharmacists, pharmacy technicians, medical assistants, revenue cycle, final counsellors, clinical research, and administrative personnel.
- 5. Create a consultative infrastructure for NETWORK members.
- 6. Understand the financial challenges and strategies for the establishment of a fiscally viable cellular therapy and immune effector therapy program.
- 7. Drafting CONCERT POSITION PAPER: "How we set-up and manage immune effector therapies in community oncology practices"

ATTENDEES

Community Oncologists, Pharmacists and Advanced Providers

SUPPORT OPPORTUNITIES

PRODUCT SHOWCASE

Cost: \$30,000 for One and \$40,000 for Two (No food service necessary)

- Representative may attend meeting
- Verbal recognition during the meeting
- Logo on the on-site program
- Post-attendee mailing list (with opt-in permission)
- Greet attendees as they enter the meeting room
- Distribute your branded items to attendees
- Company logo recognition
- Exhibit table

LUNCHEON

Cost: \$30,000

- Representative may attend meeting
- Verbal recognition during the meeting
- Logo on the on-site program
- Post-attendee mailing list (with opt-in permission)
- Greet attendees as they enter the meeting room
- Distribute your branded items to attendees
- Company logo recognition
- Exhibit table

RECEPTION

Cost: \$20,000

- Representative may attend meeting
- Verbal recognition during the meeting
- Logo on the on-site program
- Post-attendee mailing list (with opt-in permission)
- Greet attendees as they enter the meeting room
- Distribute your branded items to attendees
- Company logo recognition
- Exhibit table

ADVISORY BOARD

Cost: \$10,000 (cost of food and beverage, AV and physicians' honorariums not included)

- Invite 5 -10 physicians from the pre-registration list
- Review the most pressing issues, case studies, data, and analytics
- Gain valuable insights from physicians' input
- Provide faculty to present and lead the discussion
- Keep research at the core of the discussion
- Logo on the on-site program
- Verbal recognition during the meeting
- Post-attendee mailing list (with opt-in permission)

EDUCATIONAL SESSION SUPPORTER

Cost: \$10,000

- Representative may attend Supported Educational Session
- Logo in the on-site program
- Exhibit table

BRONZE LEVEL

Cost: \$6,000

- Logo in the on-site program
- Exhibit table

SUPPORT AGREEMENT The organization below has elected to


Hematology Education, Inc. for the space

enter this contract with Indy

and/or services indicated below.

Concert Network

Friday, February 23, 2024



SUPPORTER OPPORTUNITIES

One - Product Showcase	\$30,000
Two - Product Showcases	\$40,000
Luncheon	\$30,000
Reception	\$20,000
Advisory Board	\$10,000
Educational Session Supporter	\$10,000
Bronze Level	\$6 <i>,</i> 000

Questions: Call 317-841-7171 or email Indyhr@conventionmanagers.com Visit - www.indyhematologyreview.com

PAYMENT

Option Selected_

\$

Total price for all items:

Instructions to authorize agreement:

- Make check payable to: Indy Hematology Education, Inc. (non-profit 501(c) Tax ID# 27-1725842)
- Return completed signed form and payment to: Indy Hematology Review
 135 S. Mitthoeffer Rd. Indianapolis, IN 46229

Signature – Agreeing to support the CONCERT Network Meeting